Page 30 - 2018_11-Haematologica-web

M. Arock et al.
cooperates with c-KITD816V to transform
mast cells. Blood. 2012;120(24):4846-4849.
33. Damaj G, Joris M, Chandesris O, et al. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clon- al hematologic nonmast-cell diseases. PLoS
One. 2014;9(1):e85362.
34. Hanssens K, Brenet F, Agopian J, et al.
SRSF2-p95 hotspot mutation is highly asso- ciated with advanced forms of mastocytosis and mutations in epigenetic regulator genes. Haematologica. 2014;99(5):830-835.
35. Jawhar M, Schwaab J, Schnittger S, et al. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced sys- temic mastocytosis. Leukemia. 2016;30(1): 136-143.
36. Bibi S, Langenfeld F, Jeanningros S, et al. Molecular defects in mastocytosis: KIT and beyond KIT. Immunol Allergy Clin North Am. 2014;34(2):239-262.
37. Jawhar M, Schwaab J, Schnittger S, et al. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a dis- tinct and late event. Leukemia. 2015;29(5):1115-1122.
38. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit prod- uct. J Clin Invest. 1993;92(4):1736-1744.
39. Zuluaga Toro T, Hsieh FH, Bodo J, Dong HY, Hsi ED. Detection of phospho-STAT5 in mast cells: a reliable phenotypic marker of systemic mast cell disease that reflects con- stitutive tyrosine kinase activation. Br J Haematol. 2007;139(1):31-40.
40. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocy- tosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37(6):435- 453.
41. Arock M, Akin C, Hermine O, Valent P. Current treatment options in patients with mastocytosis: status in 2015 and future per- spectives. Eur J Haematol. 2015;94(6):474- 490.
42. Georgin-Lavialle S, Lhermitte L, Suarez F, et al. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor. Eur J Haematol. 2012;89(1):47-52.
43. Alvarez-Twose I, Matito A, Morgado JM, et al. Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the lit- erature. Oncotarget. 2016;8(40):68950- 68963.
44. Simon J, Lortholary O, Caillat-Vigneron N, et al. Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature. Pathol Biol (Paris). 2004;52(5):294-299.
45. Kurosawa M, Amano H, Kanbe N, et al. Response to cyclosporin and low-dose methylprednisolone in aggressive systemic mastocytosis. J Allergy Clin Immunol. 1999;103(5):S412-420.
46. Barete S, Lortholary O, DamaJ G, et al. Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. Blood. 2015;126(8):1009-1016.
47. Akin C. Cladribine for mastocytosis: bene- fits and risks. Blood. 2015;126(8):931-932.
48. Gotlib J, Kluin-Nelemans HC, George TI, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J
Med. 2016;374(26):2530-2541.
49. Chandesris MO, Damaj G, Canioni D, et al.
Midostaurin in advanced systemic mastocy- tosis. N Engl J Med. 2016;374(26): 2605- 2607.
50. Ustun C, Gotlib J, Popat U, et al. Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic masto- cytosis. Biol Blood Marrow Transplant. 2016;22(8):1348-1356.
51. Butterfield JH, Weiler DA. In vitro sensitivity of immature human mast cells to chemotherapeutic agents. Int Arch Allergy Appl Immunol. 1989;89(2-3):297-300.
52. Kirshenbaum AS, Worobec AS, Davis TA, Goff JP, Semere T, Metcalfe DD. Inhibition of human mast cell growth and differentia- tion by interferon gamma-1b. Exp Hematol. 1998;26(3):245-251.
53. Tefferi A, Li CY, Butterfield JH, Hoagland HC. Treatment of systemic mast-cell disease with cladribine. N Engl J Med. 2001;344(4): 307-309.
54. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood. 2003;102(13): 4270-4276.
55. Pardanani A, Hoffbrand AV, Butterfield JH, Tefferi A. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res. 2004;28(2):127-131.
56. Gleixner KV, Mayerhofer M, Aichberger KJ, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood. 2006;107(2):752-759.
57. Ma Y, Zeng S, Metcalfe DD, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivi- ty profiles than wild-type kinases and those with regulatory-type mutations. Blood. 2002;99(5):1741-1744.
es to cladribine and dasatinib in rapidly pro- gressing aggressive mastocytosis. Eur J Clin Invest. 2008;38(11):869-873.
65. Purtill D, Cooney J, Sinniah R, et al. Dasatinib therapy for systemic mastocyto- sis: four cases. Eur J Haematol. 2008;80 (5):456-458.
66. Verstovsek S, Tefferi A, Cortes J, et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mas- tocytosis. Clin Cancer Res. 2008;14(12): 3906-3915.
67. Peter B, Winter GE, Blatt K, et al. Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth. Leukemia. 2016;30(2):464-472.
68. Gleixner KV, Peter B, Blatt K, et al. Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V. Haematologica. 2013;98(9):1450-1457.
69. Krauth MT, Mirkina I, Herrmann H, Baumgartner C, Kneidinger M, Valent P. Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells. Clin Exp Allergy. 2009;39(11):1711-1720.
70. Valent P, Akin C, Hartmann K, et al. Midostaurin: a magic bullet that blocks mast cell expansion and activation. Ann Oncol. 2017;28(10):2367-2376.
71. DeAngelo DJ, George TI, Linder A, et al. Efficacy and safety of midostaurin in patients with advanced systemic mastocyto- sis: 10-year median follow-up of a phase II trial. Leukemia. 2018;32(2):470-478.
72. Fumo G, Akin C, Metcalfe DD, Neckers L. 17-Allylamino-17-demethoxygeldanamycin (17AAG) is effective in down-regulating mutated, constitutively activated KIT pro- tein in human mast cells. Blood. 2004;103(3):1078-1084.
73. Pan J, Quintas-Cardama A, Kantarjian HM, et al. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood. 2007;109(1):315-
58. Akin C, Brockow K, D'Ambrosio C, et al.
Effects of tyrosine kinase inhibitor STI571
on human mast cells bearing wild-type or
mutated c-kit. Exp Hematol. 2003;31(8):686-
692. 322.
59. Dubreuil P, Letard S, Ciufolini M, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One. 2009;4(9):e7258.
60. Lortholary O, Chandesris MO, Bulai Livideanu C, et al. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-con- trolled, phase 3 study. Lancet. 2017;389 (10069):612-620.
74. Jin Y, Chen Q, Shi X, et al. Activity of trip- tolide against human mast cells harboring the kinase domain mutant KIT. Cancer Sci. 2009;100(7):1335-1343.
75. Randall N, Courville EL, Baughn L, Afrin L, Ustun C. Bosutinib, a Lyn/Btk inhibiting tyrosine kinase inhibitor, is ineffective in advanced systemic mastocytosis. Am J Hematol. 2015;90(4):E74.
76. Manley PW, Drueckes P, Fendrich G, et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta. 2010;1804(3):445-
61. Schittenhelm MM, Shiraga S, Schroeder A,
et al. Dasatinib (BMS-354825), a dual
SRC/ABL kinase inhibitor, inhibits the
kinase activity of wild-type, juxtamem- 453.
brane, and activation loop mutant KIT iso- forms associated with human malignancies. Cancer Res. 2006;66(1):473-481.
62. Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006;108(1):286-291.
63. Gleixner KV, Mayerhofer M, Sonneck K, et al. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V mutated oncogenic variant of KIT. Haematologica. 2007;92(11):1451-1459.
64. Aichberger KJ, Sperr WR, Gleixner KV, Kretschmer A, Valent P. Treatment respons-
77. Hochhaus A, Baccarani M, Giles FJ, et al. Nilotinib in patients with systemic masto- cytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study. J Cancer Res Clin Oncol. 2015;141(11):2047- 2060.
78. Bai Y, Bandara G, Ching Chan E, et al. Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neo- plastic mast cell proliferation and mast cell activation. Leukemia. 2013;27(2):278-285.
79. Schneeweiss M, Peter B, Bibi S, et al. The KIT and PDGFRA switch-control inhibitor DCC2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. Haematologica. 2018;103(5): 799-809.
1770
haematologica | 2018; 103(11)